GPC3 CAR‑iNKT / Shanghai Pharma - LARVOL DELTA

Allogeneic CAR iNKT Cells Demonstrate Broad Therapeutic Activity Across Tumor and Autoimmune Disease Models (EACR 2026) - "These findings demonstrate that iNKT cells provide a highly effective allogeneic platform for CAR based immunotherapy across both cancer and autoimmune disease models, establishing a strong foundation for future clinical development."

Chronic Lymphocytic Leukemia • Graft versus Host Disease • Immunology • Inflammatory Arthritis • Oncology • Solid Tumor • GPC3

Allogeneic CAR‑expressing iNKT Cells as A Versatile Immunotherapy Platform for Tumors and Autoimmune Diseases in Preclinical Models (ASGCT 2026) - "Figure 2: Hep 3B cells were inoculated subcutaneously at 1x106 into the NSG mice. On the day 3, 6 and 9 after the inoculation, the mice were dosed with 18x106/mouse of the cells (CAR+=50%) via the tail vein each time."

Preclinical • Chronic Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Inflammatory Arthritis • Leukemia • Oncology • Solid Tumor • GPC3 • PD-1

Harnessing allogeneic CAR‑iNKT cells for next‑generation treatments in oncology and autoimmunity (AACR 2026) - "These findings highlight iNKT cells as a potent allogeneic platform for CAR-based immunotherapy, with broad applicability across cancer and autoimmune diseases, thereby establishing a robust basis for continued clinical investigation.Ethics Approval: The study was approved by Medicilon's Ethics Board, approval number SWSH(YF)2025-034."

Chronic Lymphocytic Leukemia • Oncology • Solid Tumor • GPC3